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Evidence of comparative efficacy should have a formal
role in European drug approvals
Despite methodological concerns, comparative efficacy evidence should be required at the time of
drug approval, says Corinna Sorenson and colleagues, to allow patients, clinicians, and other
healthcare decision makers to determine whether a new drug is superior, equivalent, or inferior to
its existing alternatives
Corinna Sorenson research fellow1, Huseyin Naci PhD candidate1, Jonathan Cylus technical officer12,
Elias Mossialos professor and director 1 2
1LSE Health and Social Care, London School of Economics and Political Science, London WC2A 2AE, UK ; 2European Observatory on Health
Systems and Policies, London, UK
Manufacturers of new drugs need to demonstrate that their
products are efficacious and safe for a defined group of patients
to obtain market approval. However, demonstrating these
outcomes relative to existing therapies is required by regulators
only when use of placebo is deemed unethical.1 2 Regulators,
clinicians, patients, and payers therefore often lack the necessary
information to distinguish between available medicines in terms
of their comparative therapeutic value and safety.
Comparative efficacy evidence at the time of drug approval is
important, and there are methodological tools available to
generate such information. When one or more treatment
alternatives are available, demonstrating lack of inferiority
through comparative assessment should be a formal requirement,
and there are ways to support this objective in European drug
licensing.
Need for comparative efficacy evidence
When a drug comes to market, evidence on the comparative
risks and benefits is needed to help regulatory authorities to
safeguard public health from inferior and unsafe treatments, to
ensure that health technology assessment agencies and payers
make funding decisions based on the best available evidence of
different treatments, and to aid clinicians’ and patients’
understanding of what therapies work best and their appropriate
position in the treatment pathway.3 However, comparative
assessment (box 1) is often conducted or made available only
once a therapy is already on the market. This is partly because
pre-marketing comparative efficacy studies entail potential
uncertainty and risk for manufacturers, as failure to demonstrate
a therapeutic advantage over older, and less costly, alternatives
may affect drug sales or result in a drug not being approved.2
This lack of comparative assessment allows manufacturers to
differentiate their products from competitors on factors unrelated
to demonstrated relative efficacy and safety.3
Although post-market assessment, which largely focuses on
comparative effectiveness as opposed to comparative efficacy,
is important, reliance on this approach alone to determine the
relative therapeutic value of medicines can be problematic. For
instance, such studies are infrequently fulfilled by industry when
required by regulators,4 and reports communicating comparative
evidence may be biased.5 Even when objective evidence is
available, it may be difficult to shift prescribing behaviour once
a therapy is used in practice and patterns of care are established.6
Furthermore, effectiveness data are not usually available at the
time of initial assessment by regulators (and, often, payers),
resulting in important evidence gaps when new treatments are
introduced into the market. Consequently, earlier information
to ascertain the relative benefit of new drugs is needed.
A lack of early comparative efficacy evidence can result in the
widespread use of potentially less efficacious and unsafe drugs,
as highlighted by the recent case of the diabetes drug
rosiglitazone. The relative effect of rosiglitazone against
pioglitazone emerged after years of widespread use,7 where
rosiglitazone was shown to increase the risk of myocardial
infarction and cardiovascular death.8 9 A number of widely
publicised studies have also questioned the true added value
offered by new (and often more expensive) drugs compared
with existing treatments.10 11 12 The Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT), for example, demonstrated that coronary heart
disease risk was not reduced for any of the three newer and
more costly drug classes compared with older and cheaper
thiazide based diuretics.13
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Box 1 Frequently used terms in comparative drug assessment
• Efficacy—the extent to which an intervention does more good than harm under ideal circumstances
• Effectiveness—the extent to which an intervention does more good than harm when provided under the usual
circumstances of healthcare practice
• Comparative efficacy—the extent to which an intervention does more good than harm, under ideal circumstances,
compared with one or more intervention alternatives for achieving the desired results
• Comparative effectiveness—the extent to which an intervention does more good than harm compared with one or
more intervention alternatives for achieving the desired results when provided under the usual circumstances of
healthcare practice
From: High Level Pharmaceutical Forum of the European Commission
Current requirements for and availability
of comparative efficacy evidence at the
time of drug approval
The European Medicines Agency has long encouraged that,
when possible, pre-market studies should be undertaken to
establish comparative efficacy and risk,1 but has yet to set
comparative assessments as the default evidentiary standard for
market approval; rather, requirements for comparative studies
are made on a case by case basis.1 14 15
Existing estimates from Europe and the United States suggest
that comparative efficacy data are available for 50–70% of new
molecular entities at the time of market authorisation.16 17While
these estimates appear encouraging, the situation is more
complex.
Firstly, the availability of such evidence varies across therapeutic
areas. For example, comparative efficacy data are available for
89% of newmolecular entities for diabetes mellitus, versus 50%
and 44% for neurological and gastrointestinal tract conditions,
respectively.17
Also, available comparative evidence is too infrequently
accessible at the time of market authorisation: only about a
quarter of studies are published, with positive findings more
often published than negative findings.14 In the case of
rosiglitazone, it was only following a legal settlement requiring
its manufacturer to release results of all its clinical trials that
researchers could carry out a systematic analysis of available
trial data.18
Methodological considerations for
generating comparative efficacy evidence
The need for comparative efficacy assessment brings into focus
the methodological approaches available to generate such
evidence. A number of clinical study designs are available to
assess comparative efficacy, each with advantages and
disadvantages (box 2).
Direct (head to head) comparisons of one or more drug therapies
in an RCT have long been considered the gold standard for
assessing comparative efficacy. For new drugs, this is best
achieved using an active comparator trial (RaCT), where patients
are randomised to receive either the experimental drug or an
established treatment (reference or standard). Well designed
RaCTs can demonstrate comparative superiority (improved
efficacy of newmedicine against existing therapies), equivalence
(absence of a difference), or non-inferiority (that a newmedicine
is no worse than alternatives).2
However, active trials are associated with a number of
methodological issues, especially with regards to demonstrating
superiority. RaCTs must be large enough and lengthy enough
to assess clinical versus surrogate outcomes, and to detect
meaningful differences in outcomes to ascertain superiority
versus equivalence. This makes themmore expensive and longer
to conduct than placebo trials.16 In addition, selecting an
appropriate comparator is not always straightforward or feasible,
especially when a large number of similar comparators exist or
when trials are lengthy (for example, a new standard of treatment
may be adopted during the study).19 20
RaCTs also possess many of the same disadvantages inherent
to any randomised trial— namely, that they follow strict
protocols using carefully selected patient groups that may not
be representative of the wider patient population, thereby
hindering their generalisability to routine clinical practice. One
recent example is dabigatran, used in atrial fibrillation. Its
primary trial (the randomised evaluation of long term
anticoagulant therapy trial, or RE-LY), an active comparator
trial, demonstrated that dabigatran was similar to (and possibly
better than) warfarin, based on a number of clinical outcomes.
However, as RE-LY excluded patients with relevant
comorbidities such as renal insufficiency, superiority claims
were complicated by concerns over the generalisability of
findings. For instance, trial results may not be applicable to
settings where patients receive warfarin with excellent
international normalised ratio control.21
In light of some of these challenges, other research approaches
have been proposed to generate comparative efficacy evidence,
offering more flexibility than traditional RCT designs in terms
of their design, conduct, and implementation. These include,
but are not limited to, adaptive and pragmatic trial designs,
prospective network meta-analyses, and observational studies.
RCTs can be designed with adaptive features that allow for
ongoing changes in trial design in response to emerging external
information (for example, evidence from systematic reviews or
observational studies).22 Such features provide opportunities to
include (or exclude) relevant comparators and to reduce the
sample size, time, or cost requirements of studies, improving
both the efficiency and relevance of trial results. However, there
is concern that following adaptations the actual patient
population could deviate from the original target patient
population, leading to erroneous claims of efficacy. Major
adaptations of trials may also result in a trial that is unable to
address the questions it intends to answer.
Pragmatic clinical trials impose fewer restrictions on patient
populations and practice settings than RCTs by conducting
studies in routine clinical settings, and generally allow for
inclusion of a wider range of outcomes (quality of life, longer
term effect, for example).23 Consequently, they are better able
to parallel clinical practice, capturing both comparative efficacy
and effectiveness information. However, as a subset of RCTs,
pragmatic clinical trials share some of the similar
methodological and ethical challenges. Moreover, they often
require higher sample sizes than traditional clinical trials given
their less tightly controlled design.
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Box 2 Advantages and disadvantages of study design options for assessing comparative efficacy
Traditional active comparator randomised controlled trials (RaCTs)
Patients are randomised to receive an experimental or standard treatment (with or without an additional group receiving
placebo).
Advantages: Gold standard for determining whether a drug works–high internal validity; most informative if three armed
design, including the experimental drug, standard treatment, and placebo. Randomisation ensures that there are minimal
systematic differences between patient groups before treatment. Carefully controlled research environments in traditional
designs ensure minimal systematic differences in how groups receive treatment.
Disadvantages: Demonstrating superiority, equivalence, or non-inferiority is challenging as the number of active
comparators increases. Strict selection criteria in traditional designs may limit generalisability of findings to broader
patient populations in routine clinical practice. Large sample sizes usually required. Costly and take a long time to
complete. Owing to short durations, important side effects may go undetected. Address comparative efficacy only.
Adaptive clinical trials
A type of randomised controlled trial designed to change or adapt in response to information generated during the trial.
Advantages: Allow trial design to be changed during the course of the study based on new data. May reduce the sample
size, time, or cost requirements of studies, thereby enhancing efficiency. Ability to include or exclude relevant comparators
can enhance clinical relevance of trial results.
Disadvantages: Adaptations may result in difficulty addressing original research questions. Changes in patient population
may deviate from original target population.
Pragmatic clinical trials
A type of randomised controlled trial (RCT) of viable treatments specifically designed to address practical questions
about the risks, benefits, and costs of an intervention as they would occur in routine clinical practice.
Advantages: High external validity. Impose only minimal restrictions in patient population and research environment to
parallel routine clinical practice. Can address both comparative efficacy and effectiveness.
Disadvantages: Subset of RCTs; therefore similar methodological and ethical challenges. Maymask small true differences
between treatments.
Network meta-analyses
A form of meta-analysis comparing multiple treatments using data from direct and indirect comparisons.
Advantages: Maintain randomisation within individual trials. Assumptions are generalisations of those in established
pair wise meta-analyses. Multiple drugs can be simultaneously compared in an internally coherent analysis by combining
evidence from head to head trials and indirect comparisons. Less expensive than randomised trials. When designed
prospectively, analyses can deliberately introduce heterogeneity, enhancing the generalisability of trial findings. Can
address both comparative efficacy and effectiveness.
Disadvantages: Indirect evidence may not be consistent with direct evidence. Share the same limitations as randomised
trials. Although randomisation is maintained within trials, the relation across trials is observational. Clinical and statistical
comparability of trials (homogeneity, similarity, and consistency of evidence) may require expert judgment.
Observational studies
A type of study where patients receiving a particular treatment are observed rather than being assigned to treatment
randomly.
Advantages: Representative of routine clinical practice by observing actual patient and prescriber practices. Possibility
of evaluating a large number of comparators at relatively low cost and high speed. Useful for studies of rare conditions
without any known treatments and for examining multiple treatment paradigms simultaneously.
Disadvantages: Prone to confounding: measurable or immeasurable factors (such as underlying differences in patient
groups before treatment, differences in patient selection, and adherence to treatment) may affect the outcomes of
interest. Methodological tools to minimise confounding generally cannot remove all bias. Information normally not
available at the time of market approval.
Network meta-analyses, an extension of meta-analyses, assess
the comparative efficacy of treatments when they have not been
compared directly in a randomised trial, but have each been
compared with other treatments.24 If designed prospectively,
these techniques allow estimation of heterogeneity in the effect
of a drug, enhancing the generalisability of trial findings. These
approaches are particularly valuable when there are a large
number of existing comparators. However, synthesis across
trials cannot always provide sufficient assurance that underlying
differences in patient characteristics are identical or evenly
distributed across trials.25
In the absence of RCTs, observational studies allow for
retrospective analysis of data collected in routine clinical
practice. Observational methods offer the possibility of
evaluating a large number of comparators at relatively low cost
and high speed. Moreover, they provide information in a routine
care setting, including critical patient groups that are often
omitted fromRCTs.25However, owing to their non-randomised
design, they are susceptible to potential confounding. Given
that observational data are not normally available at the time of
market authorisation, this approach alone would not be sufficient
to assess pre-market comparative efficacy.
In view of these opportunities and challenges, it is clear that
comparative efficacy assessment is not necessarily a panacea.
No particular study design alone is ideal for assessing
comparative efficacy and there is the inherent challenge of
ensuring studies adequately address the most relevant clinical
and policy questions to support safe and effective use of new
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therapies. Some approaches may be more appropriate under
certain conditions (such as with complex patient populations)
and with different goals in mind (safety assessment,
generalisability, for example), and the accurate interpretation
of resulting evidence is often dependent on robust design and
effective execution. Rather, available study designs should be
considered as potential complementary methodological tools.
For example, the EMA might recommend that submissions be
supported by one traditional and one pragmatic RCT and, where
possible, collect cost and quality of life data. This would help
ensure that clinically relevant evidence on the benefits and risks
of new drugs is collected and considered, and would facilitate
meeting the downstream information needs of health technology
assessment agencies and payers. Similarly, observational studies
or network meta-analyses accompanying submission of clinical
trials could strengthen pre-market comparative assessments.
Future directions toward formalising the
role of comparative efficacy in drug
licensing
Comparative efficacy assessment at the time of drug approval
serves as an important tool to help ensure that the most
beneficial and safest treatments reach patients and that limited
healthcare resources are invested wisely. Therefore, despite
existing methodological complexities, comparative efficacy
evidence should have a formal role in drug licensing decisions;
a position increasingly supported by the EMA and European
Commission.26 27 The EMA, in particular, has recommended
RaCTs when a new drug might be associated with safety or
inferiority concerns.26However, we propose that non-inferiority
be recommended for all conditions where alternative treatment
options exist, which would help address the current variability
in availability of such evidence across therapeutic areas (see
table⇓). While evidence of superiority is ideal, regulators would
argue that prescribers need multiple options available on the
market to individualise therapy for patients.28 It will, of course,
be important to further substantiate such scenarios and
transparently outline study requirements (for example, the
potential requirement of an RaCT and PCT) and possible
exceptions. If study criteria or evidence standards are set
unrealistically high or are unclear, manufacturers may
prematurely terminate development programmes for potentially
valuable drugs, or authorisation may be delayed. In attempts to
arrive at a feasible approach, regulatory authorities could
consider use of so called progressive licensing in certain
contexts. For example, a drug could be initially approved for a
defined population based on short term trials collecting surrogate
outcomes, but later extended to a broader population following
availability of post-market data with clinically meaningful
outcomes. The EMA has expressed interest in this approach.29
Moving toward these ends will also require strategies to enhance
the performance and accessibility of comparative efficacy
studies. An important first step is to achieve open dialogue and
agreement between the EMA, manufacturers, payers, and
governments on the outstanding methodological questions and
hurdles associated with these types of studies. An independent
EMA advisory board could be established to lead such
discussions and ultimately provide guidance on: what type of
study design(s) can be accepted as fit for purpose for generating
comparative efficacy evidence; standards for comparator
selection and assessed endpoints; dosing schemes; sample size
requirements to demonstrate the margin of superiority,
equivalence or non-inferiority; and options to make the conduct
of comparative studies more efficient. In addition, the board
should collaborate with national health technology assessment
agencies (such as the National Institute for Health and Clinical
Excellence) to achieve better congruence between licensing and
reimbursement requirements.
Finally, an important limitation of present regulatory systems
is the suboptimal publication of and public access to comparative
information on the efficacy, effectiveness, and safety of new
drugs. Regulators should therefore require submission of full
data, including trial protocols and raw datasets, and adopt and
enforce a policy to publicly share available data.18 30 31 More
effective data exchange could entail housing protocols and
datasets within trial registries, enhancing the quality and
transparency of the European Public Assessment Reports,
reporting comparative evidence in product labels and marketing
materials, and through journals adopting similar data submission
requirements.3 18 32 These efforts would help ensure that
researchers have access to detailed enough data to allow
independent re-analysis of trials and potentially contribute to
improving post-market comparative effectiveness assessment.
Numerous promisingmedicines have been developed andmany
more are on the way to initial clinical trials. With this success
comes an equally important additional need—to develop a
systematic approach to evaluate the risks and benefits of these
new therapies in the context of existing alternatives. An
important initial step is to support a formal role for comparative
efficacy evidence in drug licensing.
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Table
Table 1| Potential scenarios for current versus proposed comparative efficacy evidence requirements in drug approvals
Proposed requirementsCurrent requirementsPotential scenarios
Comparative efficacy cannot be requiredComparative efficacy cannot be requiredNew medicine in a therapeutic area where no
pharmacological treatment is available
Comparative efficacy to active control is
required
Comparative efficacy to active control is requiredNew medicine in a therapeutic area where placebo
is deemed unethical and active control exists
Comparative efficacy to active control is
required for all conditions where alternative
medicines exist
Comparative efficacy to active control is recommended if: (1)
the new medicine might be associated with safety concerns
that influence mortality and morbidity, markedly impair quality
of life, or cause active treatment to be discontinued or delayed
leading to significant, long term, or irreversible harm; (2)
treatment with a medicine of inferior efficacy might conceivably
lead to significant, long term, or irreversible harm for the patient.
New medicine in a therapeutic area where placebo
is deemed ethical and one or more established
medicines are available
Sources: European Medicines Agency. Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or
more established medicines are available. EMA/759784/10. Nov 2010. European Medicines Agency. EU standard of medicinal product registration: clinical
evaluation of risk/benefit—the role of comparator studies. EMA/119319/04. Oct 2004.
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